Lancet publishes ground-breaking three-paper series on pulmonary hypertension, the first of which is co-authored by a patient and patient advocate!

📣 Yesterday, August 14 2023, the The Lancet published a ground-breaking three-paper series on pulmonary hypertension. 1️⃣ In the first paper, Prof. Marc Humbert and colleagues provide an overview of the pathophysiology of pulmonary arterial hypertension, current therapeutic approaches, and emerging treatment options, with a forward-looking discussion of innovative solutions for future clinical trials. We […]

Lancet publishes ground-breaking three-paper series on pulmonary hypertension, the first of which is co-authored by a patient and patient advocate! Read Post »

Lay summary of the 2022 ESC/ERS clinical guidelines on the diagnosis and treatment of pulmonary hypertension now available in 11 languages!

“Diagnosing and treating pulmonary hypertension – understanding the professional guidelines” is an easy to understand summary of the joint European Society of Cardiology (ESC) and European Respiratory Society (ERS) clinical guidelines for pulmonary hypertension (PH). It was published on the European Lung Foundation (ELF) website on 02/11/2022. It is for people with pulmonary hypertension, or

Lay summary of the 2022 ESC/ERS clinical guidelines on the diagnosis and treatment of pulmonary hypertension now available in 11 languages! Read Post »

Recording now available for the PHA Europe webinar with Prof. Sean Gaine, May 4, 2023, on “Work in progress: Emerging hope in PH”

On the occasion of World Pulmonary Hypertension Day PHA Europe organised a live webinar with Prof. Sean Gaine, titled «Work in Progress: Emerging Hope in PH». on May 4th at 7 pm CET. Prof. Sean Gaine is Consultant Respiratory Physician at Mater Misericordiae University Hospital in Dublin, Ireland, and director of the National Pulmonary Hypertension

Recording now available for the PHA Europe webinar with Prof. Sean Gaine, May 4, 2023, on “Work in progress: Emerging hope in PH” Read Post »

“From Diagnosis of CTEPH to Triumph: Rishabh’s Journey of Resilience and Restoration”, May 31, 2023

Author: Pisana Ferrari, May 25, 2023, based on interview Introduction In the past few decades, significant strides have been made in the field of chronic thromboembolic pulmonary hypertension (CTEPH), encompassing enhanced disease comprehension, innovative therapies and surgical advancements. However, living with CTEPH continues to pose physical, practical, emotional, and social challenges for patients, families, and

“From Diagnosis of CTEPH to Triumph: Rishabh’s Journey of Resilience and Restoration”, May 31, 2023 Read Post »

“My Journey with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)”, Gabriele Valentini, May 29, 2023

Gabriele, a 47-year-old Italian national residing in Brescia, bravely opens up about his personal journey with Chronic Thromboembolic Pulmonary Hypertension (CTEPH), aiming to raise crucial awareness within the pulmonary hypertension community. By sharing his experience, he hopes to shed light on this condition and its impact, offering support and insights to those who may be

“My Journey with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)”, Gabriele Valentini, May 29, 2023 Read Post »

Pulmonary endarterectomy (PEA) Leads to Long-term QOL Improvement in People With CTEPH, study suggests, American Journal of Managed Care

Pulmonary endarterectomy (PEA) is the recommended first-line treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), if they qualify for the procedure. Alternative therapies include balloon pulmonary angioplasty (BPA) or medical therapy. An article by Jared Kaltwasser for the American Journal of Managed Care, dated April 17, 2023, presents the results of a Swedish single

Pulmonary endarterectomy (PEA) Leads to Long-term QOL Improvement in People With CTEPH, study suggests, American Journal of Managed Care Read Post »

Information resources on chronic thromboembolic pulmonary hypertension (CTEPH) by the Pulmonary Hypertension Association of Canada, PHA Canada

Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the two rare forms of pulmonary hypertension. It is the result of multiple or recurrent blood clots in the lungs. It is within Group 4 of the current official pulmonary hypertension classification. Learn more about CTEPH at this link on the PHA Canada website

Information resources on chronic thromboembolic pulmonary hypertension (CTEPH) by the Pulmonary Hypertension Association of Canada, PHA Canada Read Post »

4th Baltic Pulmonary Hypertension and Circulation Conference, April 21, 2023

The 4th Baltic Pulmonary Hypertension and Circulation Conference took place in Riga, Latvia on April 21, 2023. It provided an opportunity to hear about the latest developments in the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension from international experts – Prof. Marcin Kurzyna from Poland and Prof. Olivier Sitbon from France, as well as leading experts

4th Baltic Pulmonary Hypertension and Circulation Conference, April 21, 2023 Read Post »

“The ‘Ten Commandments’ of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension”, European Heart Journal, February 1, 2023

An interesting summary of the key ten take home messages of the ESC/ERS clinical guidelines for the diagnosis and treatment of pulmonary hypertension by six members of the Task Force who developed them (2020-2022). Features a useful infographic. Collaboration with patient associations is recommended in commandment n°10! A pdf version of the article can be

“The ‘Ten Commandments’ of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension”, European Heart Journal, February 1, 2023 Read Post »

World Pulmonary Hypertension Symposium: Barcelona, June 29-30/July 1, 2024

The World Pulmonary Hypertension Symposia (WSPH) series, started in Geneva in 1973, have been held every 5 years since the Evian edition in 1998: Venice 2003, Dana Point 2008, Nice 2013, Nice 2018. The WSPH have become a traditional appointment among the most authoritative pulmonary hypertension scholars worldwide. They have marked the progresses in pulmonary

World Pulmonary Hypertension Symposium: Barcelona, June 29-30/July 1, 2024 Read Post »

“Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study”, The Lancet, October 2022

RACE is a (completed) phase 3, multicentre, open-label, parallel-group, randomised controlled trial done in 23 French centres of expertise for pulmonary hypertension enrolling treatment-naive patients aged 18–80 years with newly diagnosed, inoperable chronic thromboembolic pulmonary hypertension and pulmonary vascular resistance of more than 320 dyn·s/cm5. A summary of the article is available on The Lancet

“Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study”, The Lancet, October 2022 Read Post »

The 2022 “Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension” by the European Society of Cardiology (ESC) and European Respiratory Society (ERS)

The work of two years of the Task Force in charge of the new European Society of Cardiology (ESC) and European Respiratory Society (ERS) joint Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension has finally come to an end. The new guidelines were officially presented yesterday at the ESC Annual Congress in Barcelona

The 2022 “Clinical Guidelines for the diagnosis and treatment of pulmonary hypertension” by the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Read Post »

What is chronic thromboembolic pulmonary hypertension? The President of PHASSc, the Turkish pulmonary hypertension association, interviews three medical experts for this educational video

What is chronic thromboembolic pulmonary hypertension? The President of PHASSc, the Turkish pulmonary hypertension association, interviews three medical experts for this educational video.

What is chronic thromboembolic pulmonary hypertension? The President of PHASSc, the Turkish pulmonary hypertension association, interviews three medical experts for this educational video Read Post »

Educational video about chronic thromboembolic pulmonary hypertension by Prof. Dr. Bedrettin Yildizeli from the Marmara University in Turkey

Educational video about chronic thromboembolic pulmonary hypertension by Prof. Dr. Bedrettin Yildizeli from the Marmara University in Turkey, shared by PAHSSc, the Turkish pulmonary hypertension patient association. The video che can be viewed on the PAHSSc YouTube channel at this link

Educational video about chronic thromboembolic pulmonary hypertension by Prof. Dr. Bedrettin Yildizeli from the Marmara University in Turkey Read Post »

Educational video about chronic thromboembolic pulmonary hypertension by RespiFil, the French national network for respiratory diseases

Excellent educational video in French language about chronic thromboembolic pulmonary hypertension, developed by RespiFil. Discusses causes of chronic thromboembolic pulmonary hypertension, symptoms, diagnostic work up, treatments. Features interviews with French PH experts from the French Network of PH (Pulmotension) including Prof. Marc Humbert from the University Hospitals of Paris-Sud Bicêtre, Le Kremlin-Bicêtre (France), and a

Educational video about chronic thromboembolic pulmonary hypertension by RespiFil, the French national network for respiratory diseases Read Post »

TRANSLATE »
Scroll to Top